Abecma (idecabtagene vicleucel) is a brand-name infusion prescribed for multiple myeloma in certain adults. Abecma is not known to interact with other medications or supplements. But it can ...

CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...

2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

Abecma（idecabtagene vicleucel）是同类首创的针对 B 细胞成熟抗原 (BCMA) 的自体CAR-T 细胞疗法，BCMA 是一种在多发性骨髓瘤恶性细胞上表达的蛋白质。 它是一种个性化的免疫疗法，可识别并结合 BCMA，导致表达 BCMA 的细胞死亡。，此前该疗法至少接受过三种治疗方法 ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement. Bristol Myers Squibb is stepping in to buy its Abecma partner 2seventy bio ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

The best ad blockers are unfortunately very necessary to survive on the modern internet. It doesn't matter which sites you browse, there's the risk of being harassed by pop-ups, tracker cookies ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...

The decision came right after the US regulator also cleared Bristol-Myers Squibb and 2seventy bio’s rival CAR-T Abecma as a third-line therapy for relapsed or refractory multiple myeloma ...

“2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma,” said Chip Baird, chief executive ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...